basal bolus insulin therapy — Competitive Intelligence Brief

basal bolus insulin therapy (basal bolus insulin therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin therapy. Area: Diabetes.

marketed Insulin therapy Insulin receptor Diabetes Small molecule

Target snapshot

basal bolus insulin therapy (basal bolus insulin therapy) — Consorci Sanitari Integral. Basal bolus insulin therapy replaces the body's natural insulin secretion by providing a long-acting basal insulin dose once or twice daily plus rapid-acting bolus insulin doses with meals to control blood glucose.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
basal bolus insulin therapy TARGET	basal bolus insulin therapy	Consorci Sanitari Integral	marketed	Insulin therapy	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin therapy class)

1. Consorci Sanitari Integral · 1 drug in this class
2. Shanghai Jiao Tong University School of Medicine · 1 drug in this class